logo
Plus   Neg
Share
Email

Eli Lilly Reports Positive Results From Interim Analysis Of Phase 3 MonarchE Study

Eli Lilly and Company (LLY) said the results from a pre-planned interim analysis of the Phase 3 monarchE study of Verzenio (abemaciclib) in combination with standard adjuvant endocrine therapy has met the primary endpoint of invasive disease-free survival, significantly decreasing the risk of breast cancer recurrence or death compared to standard adjuvant endocrine therapy alone. The safety profile was consistent with that observed in other Verzenio studies.

Lilly plans to present the data from the interim analysis at a medical meeting later this year. The monarchE trial will continue through the completion date, anticipated for June 2027.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
American Airlines has extended its offer to waive change fees for customers who purchase tickets for travel, until March 31 in response to lower travel demand due to the coronavirus pandemic. This means that travelers are provided additional flexibility by not asking them to pay penalties for changing the origin and destination cities. Lancaster Foods LLC has recalled certain conventional processed butternut squash items citing the potential to be contaminated with Listeria Monocytogenes, the U.S. Food and Drug Administration said. The products recalled included Autumn Medley, Butternut Squash Noodles, Butternut Squash Planks, Squash Noodle Medley, Butternut Squash Chunks, and Veggie Rice Blend in various measures. Amazon.com Inc. has offered to help the newly sworn-in US President Joe Biden with speedy delivery of Covid-19 vaccines across the United States amid the ongoing pandemic crisis. The e-commerce giant, whose majority of workers are in the frontline of the pandemic, reiterated its request to prioritize its essential workers to receive the vaccines at the earliest appropriate time.
Follow RTT